Trumps Presidential Income Mandate

Dear Reader,

If $68 billion were being handed out tomorrow, you’d expect to hear about it everywhere.

But according to Brad Thomas — a former advisor to President Trump — the media and Wall Street don’t want you to know about the up to $68 billion up for grabs.

In other words, that’s $8 million being paid out EVERY hour.

And these payouts were just reinforced by a mandate signed into law by President Trump.

trumpsigning

This is money that must be paid out by Federal law every single year — no matter what happens in the market.

Unfortunately most Americans have no idea these payouts exist.

And even fewer know how to collect them.

Brad says this isn’t by accident.

The details are buried in legal language most people don’t have time to read — and Wall Street isn’t incentivized to share.

That’s why Brad is stepping forward now.

He details how everyday Americans can access the same mandated payouts institutions have relied on for years.

In this special presentation, he blows the lid off the biggest income gift to Americans in the last 20 years.

If you’re interested in discovering how to add another source of income — and keeping more of your money in 2026, you’ll definitely want to see this.

Click here to see how these payouts work — and how some Americans are already collecting up to $10k a month.*

Regards,

Steven Longenecker
Editorial Director, Wide Moat Research

**The investment results described in this testimonial are not typical. Investing in securities carries a high degree of risk; you may lose some or all of the investment.





Monday’s Bonus Content

Is Abbott’s January Pullback a Good Time to Buy? 

By Thomas Hughes. Article Published: 1/24/2026. 

Abbott logo on tablet beside Libre glucose sensor and BinaxNOW test kit in a clinical lab setting.

In Brief

  • Abbott Laboratories’ January pullback looks driven more by sentiment than fundamentals, putting shares back near a prior accumulation zone.
  • Quarterly results showed solid sales growth, improving margins, and faster adjusted earnings growth despite a revenue miss.
  • A long dividend-growth track record and potential upside implied by analyst targets underpin the bullish rebound case.

Abbott Laboratories’ (NYSE: ABT) January 2026 price pullback makes the stock look attractively valued. The move—driven more by market angst than by any clear company weakness—appears to be a knee-jerk overreaction that has returned the shares to a buy zone.

ABT stock chart displaying the price action tentatively landing at support, though risks remain.

Virtually Unknown AI Company Solving Trillion-Dollar Problem (Ad)

Amazon has quietly poured $144 million into a secretive AI chip company, and committed to buying a staggering $650 million of their product. Why? Because this obscure startup holds the key to unleashing the full potential of Nvidia’s revolutionary Blackwell chip.Discover the company at the heart of the AI arms race.

The zone in question aligns with market action from 2022–2024, when Abbott was recovering from its post-COVID-19 revenue contraction and institutions were actively accumulating the stock. 

Abbott Laboratories Growth Accelerates

The most that can be said against Abbott’s Q4 results and guidance is that a few metrics missed market expectations. Still, revenue of $11.46 billion was up 4.5% year over year, margins improved, and adjusted earnings accelerated.

Revenue growth lagged consensus by several hundred basis points, but stronger margins offset much of that, with adjusted earnings per share (EPS) rising about 12% and coming in slightly above consensus.

Segment results underscore the strength of Abbott’s diversified healthcare portfolio.

Nutrition and Diagnostic saw declines, led by a nearly 9% drop in Nutrition, but those weaknesses were offset by solid gains in Established Pharmaceuticals and Med Tech.

Established Pharmaceuticals grew roughly 9%, helped by generics and emerging-market strength, while Med Tech expanded about 12.3%, with broad-based strength across its subsegments. 

Margin improvement was a positive takeaway, even if some measures fell short of certain analyst forecasts. A favorable product mix, strength in Med Tech, lower COVID-19-related sales and ongoing operational improvements supported margins, and management expects continued progress.

Looking ahead, the company projects roughly 10% earnings growth in 2026, outpacing revenue growth and supporting its capital-return plans. 

Abbott’s capital returns are central to the investment case. As a Dividend King, Abbott has raised its payout annually for more than 50 years and appears positioned to continue doing so. After the pullback the stock yields about 2.5%, and the payout ratio is under 50% of consensus earnings, leaving room for share buybacks—an important offset to the dilutive effects of share-based compensation—and other shareholder returns (see analysis).

Analysts Point to Robust Rebound in Abbott Laboratories Stock

Some analysts noted the revenue miss, but there were no major rating cuts or price-target reductions the morning of the release. The prevailing view remains that this is a fundamentally healthy company that can continue returning capital while reinvesting in growth.

The MarketBeat-consensus share price target implies potential upside of as much as 30%, which could push the stock to new all-time highs, while even the low-end targets imply modest upside from current levels. 

Key catalysts include an expanding Med Tech portfolio, AI integration across operations and products, margin expansion and strategic acquisitions.

The proposed acquisition of Exact Sciences is one example of how Abbott can broaden its revenue and profit streams and strengthen its product pipeline. 

Abbott’s share decline has been steep and could deepen, but institutional investors accumulated shares throughout 2025 and may act as buyers now that prices are discounted.

Early technical support appears in the $105–$110 range, though it is not yet confirmed. The downside risk is that ABT could slide further to the lower end of the target buy zone—potentially toward the $95 area—before staging a sustained rebound. 

Thank you for subscribing to DividendStocks.com’s daily newsletter for dividend and income investors that covers ex-dividend stocks, new dividend declarations, dividend stock ideas, and the latest market news.

This message is a sponsored email from Wide Moat Research, a third-party advertiser of DividendStocks.com and MarketBeat. 

This ad is sent on behalf of Wide Moat Research, 1125 N Charles St, Baltimore, MD 21201. If you would like to optout from receiving offers from Wide Moat Research please click here.


If you need assistance with your account, don’t hesitate to email our U.S. based support team at contact@marketbeat.com.

If you no longer wish to receive email from DividendStocks.com, you can unsubscribe.

© 2006-2026 MarketBeat Media, LLC. All rights reserved.
345 N Reid Place, Suite 620, Sioux Falls, SD 57103. U.S.A..

Today’s Featured Content: The DoD Just Got A New Drone Supplier (From The Tomorrow Investor)

Unknown's avatar

Published by RJ Hamster

I was born on 6 August 1956 in San Francisco, California to Janet and (the late) Richard Hovis. I grew up in Santa Monica, California where I attended elementary, junior high school, and high school (graduating in 1974), in addition to involvement in sports and recreation (Little League +, the Boy’s Club ++). Further, it was in elementary school – St. Augustine’s By-the -Sea Parish School that I found, and made the choice to truly journey with God. I attended Arizona State University from 1974 to 1977 – seeking to become an architect, however, I was not accepted, and, as such, I graduated with a Liberal Arts degree. Upon graduation from Arizona State University, I attended Cal Poly San Luis Obispo and studied City and Regional Planning at the Master’s level. I successfully completed one (1) year in a two (2) year program – I did not complete the Master’s degree in City and Regional Planning – due to personal reasons. I returned to Santa Monica where I started (October 1979) my career as graphic designer with Exxon Company, USA. I spent five years with Exxon Company, USA. While working with Exxon Company, USA I was accepted into architectural school – Sci-Arc in Southern California, however, I did not attend preferring to stay with Exxon.. In 1982 I married Laura Flosi and in April 1983 we had our one and only child – Lauren Alain Hovis – a gift from God. We moved to Phoenix, Arizona in 1984 from Los Angeles, where I went to work as a graphic designer with Kitchell CEM (from 1985 -1987). From 1987 – 1995 I was an independent contractor, and a registered representative in mortgage finance, financial management, graphic design, and drafting. Further, I attended the University of Phoenix and successfully obtained a Master’s in Business Administration (MBA) in 1982. I was also a member of the Scottsdale Jaycees, where I became very involved in community events and projects. In 1994, I accepted a cartography position with the Defense Mapping Agency in Reston, Virginia. As such, I relocated from Phoenix to Reston. In 1998, I was accepted and worked as a Visual Information Officer with the Central Intelligence Agency. In 2002, I worked as a Support Officer until my retirement (due to a need for shoulder surgery) in September 2018. Away from my Federal Government service, I have been involved in various organizations and activities in Northern Virginia. In November of 2011, I married Rebecca Ouellette in Santa Monica, California. I reside in San Tan Valley, AZ with my two hamster - Jess and Timothy, our fish, our lizard - RJ Lizard., and our cats - Pearl and Grey. As to hobbies, I enjoy playing sports, attending sporting events, mentoring individuals from financial management to hamsters, building models, photography, travel, multimedia design, managing partner for RJ Hamster, and jazz – smooth jazz to a samba or a bossa nova. Love and God Bless, Peter – aka RJ Hamster Jo hi

Leave a Comment